Brightstar Capital Partners, a private equity firm, has acquired Analyte Health, a technology-driven and direct-to-consumer digital health company. As part of the deal, Fiyyaz Pirani, Analyte’s founder, will remain CEO and maintain a significant ownership stake.
Analyte Health provides discreet, high-quality diagnostic and treatment services for various consumer wellness categories, including sexual health and hormonal therapies. The company’s platform utilizes a proprietary technology stack and a national network of laboratories and physicians to provide an integrated experience that encompasses clinical testing, virtual care, and prescription fulfillment.
The company has served millions of patients across the U.S. and is focused on expanding its offerings.
J.P. Morgan Securities advised Brightstar on the transaction, while Intrepid Investment Bankers advised Analyte.
KEY QUOTES:
“This partnership marks an exciting new chapter for us, as Brightstar brings both strategic expertise and a deep respect for the culture and customer trust we’ve built. I’m confident Brightstar’s operational resources and investment will help us scale while staying true to our mission of providing accessible, high-quality care directly to the consumer. I’m proud to continue leading the Company forward and remain fully committed as a significant shareholder.”
Fiyyaz Pirani, CEO of Analyte
“We are thrilled to welcome Analyte to the Brightstar portfolio. Analyte is a purpose-built platform at the intersection of healthcare, technology, and consumer engagement—segments we think are poised for long-term growth.”
Michael Singer, Partner at Brightstar
“With a strong founder, compelling unit economics, and multiple avenues for expansion, we believe there is a significant opportunity to build a leading brand in direct-to-consumer digital healthcare.”
Sam Totusek, Managing Director at Brightstar
